English Español
Back to Clinical Trials

Brief Title: Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors

A Phase 1, First-in-Human, Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors. The First Part of the Study is Completed and the Expansion Study is Ongoing (Reference Inclusion/Exclusion Criteria).


  • Org Study ID: CPX-POM-01-001
  • Secondary ID: N/A
  • NTC ID: NCT03348514
  • Sponsor: CicloMed LLC


This is a first-in-human, Phase I, multicenter, open label, dose escalation study to evaluate
the DLTs and MTD and to determine the recommended Phase 2 dose (RP2D) of CPX-POM administered
IV in patients with any histologically- or cytologically-confirmed solid tumor type.


The study will initially employ an accelerated escalation design, with a single patient
enrolled in each cohort (i.e., Single-Patient Cohorts). The initial patient will receive
CPX-POM at a starting dose of 30 mg/m2. Doses will be escalated (doubling), until a ≥Grade 2
toxicity (with the exception of alopecia), is encountered. Subsequently that and all
subsequent cohorts will follow a classical "3 + 3" dose escalation design.

  • Overall Status
  • Start Date
    January 15, 2018
  • Phase
    Phase 1
  • Study Type


Primary Outcome 1 - Measure: Evaluate the dose limiting toxicities (DLTs) and maximum tolerated dose (MTD)of CPX-POM

Primary Outcome 1 - Timeframe: 21 days


  • Advanced Solid Tumors


Inclusion Criteria Include:

1. Dose escalation cohorts only: Patient has histologically- or cytologically- confirmed
metastatic or advanced-stage solid malignant tumor that is refractory to standard
therapy. Patients should only be included if no therapy exists or if they have already
received all standard therapies that would be potentially curative or might provide
significant benefit.

2. Dose escalation cohorts only: Patient may have received up to 4 prior lines of
cytotoxic chemotherapy or immunotherapy for their metastatic disease (e.g., docetaxel
+ doxorubicin ± cyclophosphamide), and also may have received additional prior
endocrine therapy, as appropriate (e.g., for breast or prostate cancer), or
non-myelosuppressive therapy (e.g., bevacizumab, trastuzumab).

3. Dose escalation cohorts only: Patient has experienced progressive disease during or
following or was intolerant of their most recent treatment regimen. Supporting
information about prior progressive disease will be collected, if available.

4. Patient is male or female aged ≥18 years.

5. Patient provided signed and dated informed consent prior to initiation of any study

6. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0
(fully active, able to carry out all pre-disease activities without restriction) or 1
(unable to perform physically strenuous activity but ambulatory and able to carry out
work of a light or sedentary nature).

7. Patient has a predicted life expectancy of ≥3 months.

8. Dose escalation cohorts only: Patient has adequate renal function (creatinine ≤1.5 ×
the upper limit of normal [ULN]) or a glomerular filtration rate (GFR) of ≥50
mL/min/1.73 m^2). Expansion cohort only: Patient has a GFR of ≥30 mL/min/1.73 m^2.

9. Patient has adequate hepatic function, as evidenced by a total bilirubin ≤1.5 × ULN,
aspartate transaminase (AST), and /or alanine transaminase (ALT) ≤3 × ULN or ≤5 ×ULN,
if due to liver involvement by tumor.

10. Patient has adequate bone marrow function, as evidenced by hemoglobin ≥9.0 g/dL in the
absence of transfusion within the previous 72 hours, platelet count ≥100×10^9cells/L,
and absolute neutrophil count (ANC) ≥1.5×10^9 cells/L.

11. Patient has no significant ischemic heart disease or myocardial infarction (MI) within
6 months before the first dose of CPX-POM and currently has adequate cardiac function,
as evidenced by a left ventricular ejection fraction of >50% as assessed by
multi-gated acquisition (MUGA) or ultrasound/echocardiography (ECHO); and corrected QT
interval (QTc) <470 msec by Fridericia (QTcF). The eligibility of patients with
ventricular pacemakers for whom the QT interval may not be accurately measurable will
be determined on a case-by-case basis by the Sponsor in consultation with the Medical

12. Patient and his/her partner agree to use adequate contraception after providing
written informed consent through 3 months after the last dose of CPX-POM, as follows:

1. For women: Negative pregnancy test during Screening and at Day 1 of each
treatment cycle and compliant with a medically-approved contraceptive regimen
during and for 3 months after the treatment period or documented to be surgically
sterile or postmenopausal.

2. For men: Compliant with a medically-approved contraceptive regimen during and for
3 months after the treatment period or documented to be surgically sterile. Men
whose sexual partners are of child-bearing potential must agree to use 2 methods
of contraception prior to study entry, during the study, and for 3 months after
the treatment period.

13. Patient is willing and able to participate in the study and comply with all study

14. Expansion cohort only: Patients must have histologically confirmed MIBC (≥T2, N0-N1,
M0 per AJCC) pure or mixed histology urothelial carcinoma. Clinical node-positive (N1)
patients are eligible provided the lymph nodes (LNs) are confined to the true pelvis
and are within the planned surgical LN dissection template.

15. Expansion cohort only: The initial TURBT that showed muscularis propria invasion
should be within 8 weeks prior to beginning study therapy, when feasible. There must
be adequate evaluable tumor burden in the tissue blocks (from initial or repeat TURBT
with highest tumor content) to allow for analysis as determined by the local site

16. Expansion cohort only: Patients must be ineligible for cisplatin-based chemotherapy
due to any of the following:

1. Creatinine clearance(CrCl) <60 mL/min with Eastern Cooperative Oncology Group
(ECOG) Performance Status (PS) 0-1

2. Hearing impaired ≥ Grade 2 by CTCAE criteria

3. Neuropathy ≥ Grade 2 by CTCAE criteria

4. Heart failure New York Heart Association (NYHA) ≥ III

Exclusion Criteria Include:

Patients who meet any of the following exclusion criteria are not to be enrolled in this

1. Patient has a history of risk factors for torsade de pointes (e.g., heart failure,
hypokalemia, family history of long QT syndrome) or requires the use of concomitant
medications that prolong the QT/QTc interval during study participation. Patients
should not receive anti-emetic medications before and following Dose 1 of Cycle 1 for
each treatment cohort. However, anti-emetics such as ondansetron or granisetron that
have a mild QTc prolonging effect are allowed starting with Dose 2 of Cycle 1, if used
with caution and attention to the approved labelling.

2. Patient has an abnormal cardiac appearance/heart size, as evidenced by chest X-ray or
computed tomography (CT) scan.

3. Patient has an uncontrolled or severe intercurrent medical condition (including
uncontrolled brain metastases). Patients with stable brain metastases either treated
or being treated with a stable dose of steroids/anticonvulsants, with no dose change
within 4 weeks before the first dose of CPX-POM and no anticipated dose change, are
allowed. The decision to exclude a patient from the study for an uncontrolled or
severe intercurrent medical condition will be made by the Principal Investigator.
Examples could include epilepsy, resistant infection, or any other neurological
disease that would make clinical assessment difficult.

4. Patient underwent major surgery within 4 weeks before the first dose of CPX-POM or
received cancer-directed therapy (chemotherapy, radiotherapy, hormonal therapy,
biologic or immunotherapy, etc.) or an drug or device within 4 weeks (6 weeks for
mitomycin C and nitrosoureas) or 5 half-lives of that agent (whichever is shorter)
before the first dose of CPX-POM. A minimum of 10 days between termination of the
investigational drug and administration of CPX-POM is required. In addition, any
drug-related toxicity, with the exception of alopecia, should have recovered to ≤Grade

5. If female, patient is pregnant or breast-feeding.

6. Patient has evidence of a serious active infection (e.g., infection requiring
treatment with intravenous antibiotics).

7. Patient has active Hepatitis A infection.

8. Patient known human immunodeficiency virus (HIV) or Hepatitis B or C infection, as
such patients may be at increased risk for toxicity due to concomitant treatment and
disease-related symptoms may preclude accurate assessment of the safety of CPX POM.

9. Patient has an important medical illness or abnormal laboratory finding that, in the
Investigator's opinion, would increase the risk of participating in this study.

10. Patient is taking warfarin.

11. Patient has a history of other malignancy treated with curative intent within the
previous 5 years with the exception of adequately treated non-melanoma skin cancer or
carcinoma in situ of the cervix. Patients with previous invasive cancers are eligible
if the treatment was completed more than 5 years prior to initiating current study
treatment, and there is no evidence of recurrent disease.

12. Patient has known allergy or hypersensitivity to components of CPX-POM.

13. Patient is taking any iron replacement therapy administered IV, IM, or orally due to
the potential for loss of anticancer activity due to drug and metabolites chelating

Exclusion criteria for Expansion cohort:

Patients who meet any of the following exclusion criteria are not to be enrolled in the
Expansion Cohort of this study.

1. Baseline GFR <30 mL/min/1.73 m^2.

2. Women must not be pregnant or breastfeeding since we do not know the effects of
CPX-POM on the fetus or breastfeeding child.

3. Patients may not have concurrent upper urinary tract (i.e. ureter, renal pelvis)
invasive urothelial carcinoma. Patients with history of non-invasive (Ta, Tis) upper
tract urothelial carcinoma that has been definitively treated with at least one
post-treatment disease assessment (i.e. cytology, biopsy, imaging) that demonstrates
no evidence of residual disease are eligible.

4. Patients may not have another malignancy that could interfere with the evaluation of
safety or efficacy of the study drugs. Patients with a prior malignancy will be
allowed without study chair approval in the following circumstances:

1. Not currently active and diagnosed at least 3 years prior to the date of

2. Non-invasive diseases such as low risk cervical cancer or any cancer in situ.

3. Localized (early stage) cancer treated with curative intent (without evidence of
recurrence and intent for further therapy), and in which no chemotherapy was
indicated.( (e.g. low/intermediate risk prostate cancer, etc.).

5. Patients may not have undergone major surgery with the exception of TURBT (e.g.
intra-thoracic, intra-abdominal or intra-pelvic), open biopsy or significant traumatic
injury or specific anti-cancer treatment ≤ 4 weeks prior to starting study drug, or
patients who have had percutaneous biopsies or placement of vascular access device ≤ 1
week prior to starting study drug, or who have not recovered from side effects of such
procedure or injury.

6. Patients must not have clinically significant cardiac disease.

7. Patients may not have chronic active liver disease or evidence of acute or chronic
Hepatitis B Virus (HBV) or Hepatitis C (HCV).

8. Patients may not have known diagnosis of human immunodeficiency virus (HIV) infection.
Testing is not required in absence of clinical suspicion.

9. Patients may not have known diagnosis of any condition (e.g. post-hematopoietic or
solid organ transplant, pneumonitis, inflammatory bowel disease, etc.) that requires
chronic immunosuppressive therapy. Usage of non-steroidal anti-inflammatory
medications (NSAIDS) for the treatment of osteoarthritis and uric acid synthesis
inhibitors for the treatment of gout are permitted.

10. Patients with any serious and/or uncontrolled concurrent medical conditions (e.g..,
active or uncontrolled infection, uncontrolled diabetes) or psychiatric illness that
could, in the investigator's opinion, cause unacceptable safety risks or potentially
interfere with the completion of the treatment according to the protocol are not

11. Patients may not have any live viral vaccine used for prevention of infectious
diseases within 4 weeks prior to study drug(s).

12. Patients unwilling or unable to comply with the protocol.

Gender: All

Minimum Age: N/A

Maximum Age: 18 Years

Healthy Volunteers: No


Name: John Taylor

Role: Principal Investigator

Affiliation: Kansas Univeristy Medical Center

Overall Contact

Name: John Taylor

Phone: N/A

Email: N/A


Facility Status Contact
Facility: Sarah Cannon Research Institute
Denver, Colorado 80218
United States
Status: Recruiting Contact:
Kari Koga
Facility: Kansas University Medical Center
Kansas City, Kansas 66160
United States
Status: Recruiting Contact:
Christina Hopkins